Swiss National Bank
PDLI

Swiss National Bank’s PDL BioPharma, Inc. PDLI Stock Holding History

Swiss National Bank’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-250,900
Closed -$790K – 2554
2020
Q3 		$790K Buy
250,900
+8,700
+4% +$27.8K ﹤0.01% 2218
2020
Q2 		$705K Buy
242,200
+19,800
+9% +$62.6K ﹤0.01% 2283
2020
Q1 		$627K Hold
222,400
– – ﹤0.01% 2079
2019
Q4 		$722K Sell
222,400
-4,100
-2% -$11.9K ﹤0.01% 2293
2019
Q3 		$489K Sell
226,500
-45,200
-17% -$121K ﹤0.01% 2367
2019
Q2 		$853K Buy
271,700
+5,600
+2% +$18.2K ﹤0.01% 2202
2019
Q1 		$990K Buy
266,100
+9,000
+4% +$30.4K ﹤0.01% 2069
2018
Q4 		$746K Sell
257,100
-12,100
-4% -$33.2K ﹤0.01% 2160
2018
Q3 		$708K Hold
269,200
– – ﹤0.01% 2310
2018
Q2 		$630K Hold
269,200
– – ﹤0.01% 2387
2018
Q1 		$791K Hold
269,200
– – ﹤0.01% 2209
2017
Q4 		$738K Buy
269,200
+22,000
+9% +$67.6K ﹤0.01% 2256
2017
Q3 		$838K Hold
247,200
– – ﹤0.01% 2168
2017
Q2 		$611K Hold
247,200
– – ﹤0.01% 2344
2017
Q1 		$561K Hold
247,200
– – ﹤0.01% 2340
2016
Q4 		$524K Hold
247,200
– – ﹤0.01% 2374
2016
Q3 		$828K Hold
247,200
– – ﹤0.01% 2096
2016
Q2 		$776K Hold
247,200
– – ﹤0.01% 2112
2016
Q1 		$793K Buy
247,200
+51,100
+26% +$159K ﹤0.01% 2046
2015
Q4 		$694K Hold
196,100
– – ﹤0.01% 2074
2015
Q3 		$986K Buy
196,100
+27,200
+16% +$156K ﹤0.01% 1790
2015
Q2 		$1.09M Buy
168,900
+2,900
+2% +$19.4K ﹤0.01% 1743
2015
Q1 		$1.17M Buy
166,000
+3,800
+2% +$27.5K ﹤0.01% 1681
2014
Q4 		$1.25M Buy
162,200
+3,900
+2% +$30.9K ﹤0.01% 1590
2014
Q3 		$1.18M Sell
158,300
-2,900
-2% -$26.9K ﹤0.01% 1565
2014
Q2 		$1.56M Buy
161,200
+9,600
+6% +$85.6K 0.01% 1424
2014
Q1 		$1.26M Buy
151,600
+35,400
+30% +$303K ﹤0.01% 1548
2013
Q4 		$981K Hold
116,200
– – ﹤0.01% 1519
2013
Q3 		$926K Sell
116,200
-6,600
-5% -$53.1K ﹤0.01% 1504
2013
Q2 		$948K Buy
+122,800
New +$958K ﹤0.01% 1467

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Swiss National Bank's PDLI Position: Q4 2020 in Review

Swiss National Bank sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 250,900 shares — an estimated $790K sold.

Swiss National Bank first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $1.56M in Q2 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Swiss National Bank reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Swiss National Bank sold 250,900 PDL BioPharma, Inc. shares in Q4 2020, an estimated $790K.
  • Swiss National Bank first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
  • Swiss National Bank's PDL BioPharma, Inc. position peaked at $1.56M in Q2 2014.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Swiss National Bank's 13F filing for Q4 2020, filed 5 Feb 2021.